V. Setola

发表

Automated design of ligands to polypharmacological profiles

Maria F. Sassano, G. R. Bickerton, Jérémy Besnard, 2012, Nature.

Predicting new molecular targets for known drugs

Michael J. Keiser, J. Irwin, B. Shoichet, 2009, Nature.

Identifying mechanism-of-action targets for drugs and probes

J. Irwin, B. Shoichet, V. Setola, 2012, Proceedings of the National Academy of Sciences.

Exome Sequencing in 53 Sporadic Cases of Schizophrenia Identifies 18 Putative Candidate Genes

D. Rujescu, M. Leboyer, S. Antonarakis, 2014, PloS one.

Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure

Avner Schlessinger, Bryan L. Roth, Brian K. Shoichet, 2011, Nature chemical biology.

Chemical Informatics and Target Identification in a Zebrafish Phenotypic Screen

Bryan L. Roth, Brian K. Shoichet, Michael J. Keiser, 2011, Nature chemical biology.

Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.

Bryan L Roth, V. Setola, Xi-Ping Huang, 2010, Assay and drug development technologies.

A Chemocentric Informatics Approach to Drug Discovery: Identification and Experimental Validation of Selective Estrogen Receptor Modulators as ligands of 5-Hydroxytryptamine-6 Receptors and as Potential Cognition Enhancers

Alexander Tropsha, Bryan L Roth, A. Tropsha, 2012 .

Design, synthesis, and validation of a β-turn mimetic library targeting protein-protein and peptide-receptor interactions.

Bryan L. Roth, Dale L. Boger, Peter K. Vogt, 2011, Journal of the American Chemical Society.

N-Alkyl-octahydroisoquinolin-1-one-8-carboxamides: a Novel Class of Selective, Nonbasic, Nitrogen-Containing κ-Opioid Receptor Ligands.

V. Setola, B. Roth, P. Ghosh, 2010, ACS medicinal chemistry letters.

N-Alkyl-octahydroisoquinolin-1-one-8-carboxamides: Selective and Nonbasic κ-Opioid Receptor Ligands

V. Setola, B. Roth, P. Ghosh, 2010 .

Identification and Validation of Small Molecules That Enhance Recombinant Adeno-associated Virus Transduction following High-Throughput Screens

V. Setola, R. Samulski, M. Hirsch, 2016, Journal of Virology.

Reduction of GPSM3 expression akin to the arthritis-protective SNP rs204989 differentially affects migration in a neutrophil model

V. Setola, B. Gall, A. Schroer, 2016, Genes and Immunity.

Labdane diterpenoids from Leonotis leonurus.

V. Setola, B. Roth, D. Ferreira, 2013, Phytochemistry.

Bis-spirolabdane diterpenoids from Leonotis nepetaefolia.

V. Setola, B. Roth, D. Ferreira, 2012, Journal of natural products.

5-HT(2B) antagonism arrests non-canonical TGF-β1-induced valvular myofibroblast differentiation.

Joshua D. Hutcheson, V. Setola, W. Merryman, 2012, Journal of molecular and cellular cardiology.

Synthesis and receptor profiling of Stemona alkaloid analogues reveal a potent class of sigma ligands

V. Setola, B. Roth, Benjamin Neuenswander, 2011, Proceedings of the National Academy of Sciences.

Serotonin and Angiotensin Receptors in Cardiac Fibroblasts Coregulate Adrenergic-Dependent Cardiac Hypertrophy

V. Setola, L. Monassier, J. Launay, 2008, Circulation research.

Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist.

V. Setola, L. Liu-Chen, K. Freeman, 2021, Handbook of experimental pharmacology.

Role of the N-Terminal Region in G Protein–Coupled Receptor Functions: Negative Modulation Revealed by 5-HT2B Receptor Polymorphisms

V. Setola, L. Maroteaux, I. Moutkine, 2013, Molecular Pharmacology.

Role of the N-Terminal Region in G Protein – Coupled Receptor Functions : Negative Modulation Revealed by 5-HT 2 B Receptor Polymorphisms s

V. Setola, L. Maroteaux, I. Moutkine, 2013 .

Role of the N-terminal region in G protein-coupled receptor functions : negative modulation revealed by 5-HT 2 B receptor polymorphisms

V. Setola, L. Maroteaux, I. Moutkine, 2013 .

Four single nucleotide polymorphisms in genes involved in neuronal signaling are associated with Opioid Use Disorder in West Virginia.

V. Setola, D. Siderovski, L. Lander, 2019, Journal of opioid management.

Neurochemical profiles of some novel psychoactive substances.

V. Setola, Xi-Ping Huang, B. Roth, 2013, European journal of pharmacology.

Modified Receptor Internalization upon Coexpression of 5-HT1B Receptor and 5-HT2B Receptors

V. Setola, J. Launay, L. Maroteaux, 2007, Molecular Pharmacology.

Structural Determinants of G-protein α Subunit Selectivity by Regulator of G-protein Signaling 2 (RGS2)*

S. Knapp, V. Setola, B. Roth, 2009, The Journal of Biological Chemistry.

Protein kinase C‐mediated down‐regulation of β2‐adrenergic receptor and gene expression in rat C6 glioma cells

V. Setola, P. Fishman, M. Leavitt, 2001 .

Special Section on The Opioid Crisis Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine s

V. Setola, S. Kinsey, T. Prisinzano, 2019 .

1,2,3,4-tetrahydrocarbazoles as 5-HT6 serotonin receptor ligands.

V. Setola, B. Roth, R. Glennon, 2004, Bioorganic & medicinal chemistry letters.

Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors.

V. Setola, B. Roth, R. Guy, 2009, Journal of medicinal chemistry.

Evidence for the Involvement of Dopamine Transporters in Behavioral Stimulant Effects of Modafinil

V. Setola, B. Roth, R. Rothman, 2009, Journal of Pharmacology and Experimental Therapeutics.

Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.

V. Setola, B. Roth, S. Eyunni, 2012, Bioorganic & medicinal chemistry.

An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.

L. Iversen, J. Dalley, V. Setola, 2013, Bioorganic & medicinal chemistry letters.

Discovery of a novel member of the histamine receptor family.

V. Setola, B. Roth, D. A. Shapiro, 2001, Molecular pharmacology.

Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine

V. Setola, D. Siderovski, S. Kinsey, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Deficient serotonin neurotransmission and depression-like serotonin biomarker alterations in tryptophan hydroxylase 2 (Tph2) loss-of-function mice

Benjamin D. Sachs, V. Setola, M. Caron, 2012, Molecular Psychiatry.

Development of Full Sweet, Umami, and Bitter Taste Responsiveness Requires Regulator of G protein Signaling-21 (RGS21)

V. Setola, D. Siderovski, A. Vandenbeuch, 2018, Chemical senses.

Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies

Ryan T. Strachan, V. Setola, B. Roth, 2006, The Pharmacogenomics Journal.

Single Nucleotide Polymorphisms in Chemosensory Pathway Genes GNB3, TAS2R19, and TAS2R38 Are Associated with Chronic Rhinosinusitis

V. Setola, D. Siderovski, S. Wen, 2019, International Archives of Allergy and Immunology.

RGS21, a regulator of taste and mucociliary clearance?

V. Setola, D. Siderovski, F. Willard, 2013, The Laryngoscope.

Protein kinase C-mediated down-regulation of beta(2)-adrenergic receptor and gene expression in rat C6 glioma cells.

V. Setola, P. Fishman, M. Leavitt, 2001, Journal of neurochemistry.

Binding of amine-substituted N1-benzenesulfonylindoles at human 5-HT6 serotonin receptors.

V. Setola, B. Roth, R. Glennon, 2005, Bioorganic & medicinal chemistry letters.

The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor

V. Setola, Xi-Ping Huang, B. Roth, 2013, PloS one.

Role of RGS12 in the differential regulation of kappa opioid receptor-dependent signaling and behavior

Karl T. Schmidt, V. Setola, D. Siderovski, 2019, Neuropsychopharmacology.

A role for Regulator of G protein Signaling-12 (RGS12) in the balance between myoblast proliferation and differentiation

V. Setola, D. Siderovski, Melinda D Willard, 2019, PloS one.

3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.

V. Setola, B. Roth, S. Hufeisen, 2003, Molecular pharmacology.

Identification of a new selective dopamine D4 receptor ligand.

V. Setola, B. Roth, N. Lamango, 2014, Bioorganic & medicinal chemistry.

Binding of isotryptamines and indenes at h5-HT6 serotonin receptors.

V. Setola, B. Roth, R. Glennon, 2005, Bioorganic & medicinal chemistry letters.

The Presynaptic Component of the Serotonergic System is Required for Clozapine's Efficacy

Michael J. Keiser, Bryan L Roth, John J Irwin, 2011, Neuropsychopharmacology.

Discovery of β-Arrestin–Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy

Maria F. Sassano, V. Setola, Xi-Ping Huang, 2011, Proceedings of the National Academy of Sciences.

Serotonin receptors and heart valve disease--it was meant 2B.

Bryan L Roth, Joshua D. Hutcheson, W David Merryman, 2011, Pharmacology & therapeutics.

Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.

V. Setola, B. Roth, S. Eyunni, 2012, Bioorganic & medicinal chemistry.

Orally active adenosine A(1) receptor agonists with antinociceptive effects in mice.

Joseph E. Rittiner, V. Setola, S. Frye, 2012, Journal of medicinal chemistry.

Why mice are neither miniature humans nor small rats: a cautionary tale involving 5-hydroxytryptamine-6 serotonin receptor species variants.

V. Setola, B. Roth, 2003, Molecular pharmacology.

Schizophrenia risk gene CAV1 is both pro-psychotic and required for atypical antipsychotic drug actions in vivo

V. Setola, B. Roth, M. Farrell, 2011, Translational Psychiatry.

Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment

Bryan L. Roth, V. Setola, Xi-Ping Huang, 2009, Molecular Pharmacology.

1-(1-Naphthyl)piperazine as a novel template for 5-HT6 serotonin receptor ligands.

V. Setola, B. Roth, R. Glennon, 2005, Bioorganic & medicinal chemistry letters.

Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.

Maria F. Sassano, V. Setola, M. F. Sassano, 2012, Journal of medicinal chemistry.

Photochemical activation of TRPA1 channels in neurons and animals

Michael R Hamblin, Robert W. Mills, V. Setola, 2013, Nature chemical biology.

Genetic deletion of Rgs12 in mice affects serotonin transporter expression and function in vivo and ex vivo

V. Setola, W. Wetsel, D. Siderovski, 2020, Journal of psychopharmacology.

Molecular Determinants for the Interaction of the Valvulopathic Anorexigen Norfenfluramine with the 5-HT2B Receptor

Bryan L Roth, V. Setola, B. Roth, 2005, Molecular Pharmacology.

Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.

Alexander Golbraikh, Alexander Tropsha, Christopher M Grulke, 2010, Journal of medicinal chemistry.

Michael acceptor approach to the design of new salvinorin A-based high affinity ligands for the kappa-opioid receptor.

V. Setola, B. Roth, E. Vardy, 2014, European journal of medicinal chemistry.

Regulator of G protein signaling-12 modulates the dopamine transporter in ventral striatum and locomotor responses to psychostimulants

V. Setola, D. Siderovski, Kim Wix, 2018, Journal of psychopharmacology.

["DISCOVERING THE MOLECULAR AND CELLULAR MECHANISMS UNDERLYING FENFLURAMINE-INDUCED CARDIOPULMONARY SIDE EFFECTS"]

V. Setola, 2005 .

Serotonin 5-HT2B Receptors Are Required for 3,4-Methylenedioxymethamphetamine-Induced Hyperlocomotion and 5-HT Release In Vivo and In Vitro

V. Setola, E. Valjent, D. Hervé, 2008, The Journal of Neuroscience.

Serotonin 5-HT 2 B receptors are required for 3 , 4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro

V. Setola, E. Valjent, J. Launay, 2019 .

Further evaluation of the tropane analogs of haloperidol.

V. Setola, B. Roth, N. Lamango, 2014, Bioorganic & medicinal chemistry letters.

Moderate chemical modifications of WAY-100635 improve the selectivity for 5-HT1A versus D4 receptors.

V. Setola, B. Roth, J. Scuvée-Moreau, 2012, Bioorganic & medicinal chemistry letters.

The Emergence of Serotonin 5‐HT2B Receptors as DRUG Antitargets

V. Setola, B. Roth, 2008 .

Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on ‘fen–phen’

V. Setola, B. Roth, 2005, Expert opinion on drug metabolism & toxicology.

Genetic variations in GPSM3 associated with protection from rheumatoid arthritis affect its transcript abundance

V. Setola, P. Stoilov, A. Wilson, 2015, Genes and Immunity.

The Emergence of 5-HT2B Receptors as Targets to Avoid in Designing and Refining Pharmaceuticals

V. Setola, B. Roth, 2006 .

3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.

V. Setola, B. Roth, S. Hufeisen, 2003, Molecular pharmacology.

Structural Determinants of G-protein α Subunit Selectivity by Regulator of G-protein Signaling 2 (RGS2)*

S. Knapp, V. Setola, B. Roth, 2009, Journal of Biological Chemistry.

Synthesis and receptor profiling of Stemona alkaloid analogues reveal a potent class of sigma ligands

V. Setola, B. Roth, Benjamin Neuenswander, 2011, Proceedings of the National Academy of Sciences.

Predicting new molecular targets for known drugs

Michael J. Keiser, J. Irwin, B. Shoichet, 2009, Nature.

A. Tropsha, V. Setola, B. Roth, 2012 .